Cover Image
Market Research Report

The Global Genetic Testing Market By Direct to Consumer, Prenatal, Predictive and Pharmacogenomic including Test Price and Volume Forecasts with Executive and Consultant Guides 2018 to 2020

Published by Howe Sound Research Product code 384217
Published Content info 241 Pages
Delivery time: 1-2 business days
Price
Back to Top
The Global Genetic Testing Market By Direct to Consumer, Prenatal, Predictive and Pharmacogenomic including Test Price and Volume Forecasts with Executive and Consultant Guides 2018 to 2020
Published: June 20, 2018 Content info: 241 Pages
Description

Will all newborns receive Whole Genomic Sequencing at birth? What key interest is driving Direct to Consumer?

Our facts and support = Your success.

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life for the industry. The report forecasts the market size out to 2020. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School
Table of Contents

Table of Contents

i. Genetic Testing Market - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 Genetic Testing Definition In This Report
  • 1.2 The Genomics Revolution
  • 1.3 Market Definition
    • 1.3.1 Volumes
    • 1.3.2 Prices
    • 1.3.3 Revenue Market Size
  • 1.4 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for laboratory testing

2. Market Overview

  • 2.1 Market Participants Play Different Roles
    • 2.1.1 Supplier/pharmaceutical
    • 2.1.2 Independent lab specialized/esoteric
    • 2.1.3 Independent lab national/regional
    • 2.1.4 Independent lab analytical
    • 2.1.5 Public National/regional lab
    • 2.1.6 Hospital lab
    • 2.1.7 Physician lab
    • 2.1.8 DTC Lab
    • 2.1.9 Independent Genetic Testing Lab
    • 2.1.10 Audit body
  • 2.2 Genetic Tests -Types, Examples and Discussion
    • 2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market
    • 2.2.2 Prenatal Diagnosis - New Technologies Create Opportunity
    • 2.2.3 Newborn Screening
    • 2.2.2 Diagnostic Testing
    • 2.2.3 Carrier Testing
    • 2.2.6 Predictive and Presymptomatic Testing
    • 2.2.7 Pharmacogenomics
    • 2.2.8 Forensic Testing
    • 2.2.9 Parental Testing
    • 2.2.10 Ancestral Testing
  • 2.3 Industry Structure
    • 2.3.1 Hospital's Testing Share
    • 2.3.2 Economies of Scale
    • 2.3.2.1 Hospital vs. Central Lab
    • 2.3.3 Physician Office Lab's
    • 2.3.4 Physician's and POCT
  • 2.4 Profiles of Key Companies
    • 2.4.1 Roche Molecular Diagnostics
    • 2.4.2 Illumina
    • 2.4.3 Grail
    • 2.4.4 Complete Genomics - BGI
    • 2.4.5 Qiagen
    • 2.4.6 GE Global Research
    • 2.4.7 BGI Genomics Co. Ltd.
    • 2.4.8 Oxford Nanopore Technologies
    • 2.4.9 Genomic Health
    • 2.4.10 Pacific Biosciences
    • 2.4.11 Siemens Healthcare
    • 2.4.12 23 and Me
    • 2.4.13 Ancestry.com
    • 2.4.14 Bio-Rad
    • 2.4.15 Thermo Fisher
    • 2.4.16 Fabric Genomics
    • 2.4.17 Centogene
    • 2.4.18 Gene by Gene Ltd
    • 2.4.19 Veritas Genetics
    • 2.4.20 Dante Labs
    • 2.4.21 Guardiome
    • 2.4.22 Sure Genomics
    • 2.4.23 Novogene
    • 2.4.24 Helix
    • 2.4.25 Genomics Personalized Health (GPH)
    • 2.4.26 Sequencing.com
    • 2.4.27 Omega Bioservices
    • 2.4.28 ORIG3N
    • 2.4.29 Human Longevity, Inc.
    • 2.4.30 Invitae
  • 2.5 Market Shares of Key Genetics Players - Analysis

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Genetic Discovery Creates New Diagnostic Markets
    • 3.1.2 Aging Population a Boon for Diagnostics.
    • 3.1.3 Pharmacogenomics Drives Further Growth.
    • 3.1.4 Point of Care Testing can increase demand
    • 3.1.5 Fertility Practice
    • 3.1.6 Direct to Consumer
  • 3.2 Factors Limiting Growth
    • 3.2.1 Increased Competition Lowers Price
    • 3.2.2 Lower Costs.
    • 3.2.3 Testing usage analysis curtailing growth.
    • 3.2.4 Wellness has a downside
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role.
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution
    • 3.4.2 Impact of NGS on pricing
    • 3.4.3 POCT/Self Testing Disruptive Force
    • 3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.5 CGES Testing, A Brave New World
    • 3.4.6 Biochips/Giant magneto resistance based assay

4. Genetic Testing Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
    • 4.26 Myriad Genetics to Acquire Counsyl for $375M
    • 4.27 Roche inks $2.4B deal to buy out Foundation Medicine
    • 4.28 Rapid genome sequencing could revolutionize health care
  • 4.2 Future goal in UK is for every cancer patient to have his or her whole genome sequenced
  • 4.3 Human Longevity Launches Whole Genome Product, MassMutual Partnerships
  • 4.4 Influence of Whole Genome Sequencing growing
  • 4.5 Rady Children's and Edico Genome Extend WGS Collaboration
  • 4.6 $1500 to sequence newborns in China
  • 4.8 Eurofins Acquiring PerkinElmer's NTD Laboratory Services Business
  • 4.9 GeneInsight Acquisition Boosts Sunquest's Clinical Genetics IT Platform
  • 4.10 AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep
  • 4.11 The Cooper Companies' Women's Health Care Unit Acquires Genesis Genetics
  • 4.12 Research Validates Preimplantation Genetic Diagnosis for Aneuploidy (PGD-A)
  • 4.13 New Investments in Ancestry.com to Boost DNA Business
  • 4.14 GHO Capital Announces Acquisition of DNA Diagnostics Center
  • 4.15 Scientists discover new nanoparticle, dubbed exomeres, released by tumors
  • 4.16 New DNA tests look for 190 diseases in newborn's genetic code
  • 4.17 Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia
  • 4.18 New genetic risk score could help guide screening decisions for prostate cancer
  • 4.19 Tele-genetics pilot makes genetic counseling accessible
  • 4.20 Digital Genetic Assistant OptraGURU™ Launches Today From Optra Health
  • 4.21 PacBridge Capital Partners Invests C$12M in Contextual Genomics
  • 4.22 MDxHealth 2017 Revenues Rise 35 Percent on Prostate Cancer Tests
  • 4.23 From DNA To Disease: A Diagnosis Made In Under A Day
  • 4.24 A New Tool Uses CRISPR to Uncover Genetic Mutations
  • 4.25 Sophia Genetics Gains CE-IVD Mark for Leukemia Assay
  • 4.89 Floragenex, Sedia Biosciences Merge
  • 4.90 Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health
  • 4.91 Berry Genomics Seeks Public Listing in China Via Reverse Merger
  • 4.92 Athletigen sees genetic testing as part of athletic training
  • 4.93 AncestryDNA sees huge growth in demand for genetic testing
  • 4.93 Phosphorus Raises $10 Million in Series A Funding to Build a Clinical Genomics Network
  • 4.94 NeoGenomics Q1 Revenues Jump on Genetic Test Volume Growth
  • 4.95 Nevada Population Health Study to Offer Free 23andMe Genetic Tests to Community
  • 4.96 Danaher to buy Cepheid in $4 billion deal to expand in diagnostics
  • 4.97 Floragenex, Sedia Biosciences Merge
  • 4.98 miRagen Therapeutics and Signal Genetics Agree to Merge
  • 4.99 Abbott Seeks to Exit Alere Deal
  • 4.100 Capnia, Essentialis to Merge, With Focus on Rare Disease Treatments
  • 4.101 Novartis Completes Sale of Genoptix Lab Business
  • 4.102 Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion
  • 4.103 PerkinElmer Launches Clinical Whole Genome Sequencing Services
  • 4.104 WGS and AI help clinicians scale precision oncology
  • 4.105 Veritas Genetics Buys Curoverse
  • 4.106 Dante Labs Partners With Amazon UK for Special £349 Whole Genome Sequencing
  • 4.107 Toolbox Genomics Launches Personalized Wellness App in Sequencing.com's Revolutionary App Market
  • 4.108 CDC invests in WGS to help states respond to infectious disease threats
  • 4.109 Factory contamination of medical device likely source of M. chimaera infection in patients in multiple countries
  • 4.110 IBM Watson impresses in WGS brain tumour analysis
  • 4.111 OneOme, Genome.One Partner to Offer Genetic Risk, PGx Service in Australia
  • 4.112 WGS aids in Salmonella outbreak control
  • 4.113 CombiMatrix In Merger Agreement with Invitae to be Acquired for $33 Million in Invitae Common Stock

5. Country Market Sizes - North America

  • 5.1 United States of America
    • 5.1.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 5.1.2 Predictive Testing - Volumes, Prices, Revenues
    • 5.1.3 Pharmacogenomic Testing - Volumes, Prices, Revenues
    • 5.1.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 5.1.5 All Genetic testing - Volumes, Prices, Revenues
  • 5.2 Canada
    • 5.2.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 5.2.2 Predictive Testing - Volumes, Prices, Revenues
    • 5.2.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 5.2.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 5.2.5 All Genetic testing - Volumes, Prices, Revenues

6. Country Markets - Europe

  • 6.1 France
    • 6.1.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.1.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.1.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.1.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.1.5 All Genetic testing - Volumes, Prices, Revenues
  • 6.2 Germany
    • 6.2.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.2.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.2.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.2.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.2.5 All Genetic testing - Volumes, Prices, Revenues
  • 6.3 United Kingdom
    • 6.3.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.3.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.3.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.3.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.3.5 All Genetic testing - Volumes, Prices, Revenues
  • 6.4 Spain
    • 6.4.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.4.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.4.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.4.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.4.5 All Genetic testing - Volumes, Prices, Revenues
  • 6.5 Italy
    • 6.5.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.5.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.5.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.5.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.5.5 All Genetic testing - Volumes, Prices, Revenues
  • 6.6 Russia
    • 6.6.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.6.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.6.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.6.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.6.5 All Genetic testing - Volumes, Prices, Revenues
  • 6.7 Remainder of Europe and Former Soviet Union
    • 6.7.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 6.7.2 Predictive Testing - Volumes, Prices, Revenues
    • 6.7.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 6.7.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.7.5 All Genetic testing - Volumes, Prices, Revenues

7. Country Markets - Asia Pacific

  • 7.1 China
    • 7.1.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.1.2 Predictive Testing - Volumes, Prices, Revenues
    • 7.1.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.1.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.1.5 All Genetic testing - Volumes, Prices, Revenues
  • 7.2 Japan
    • 7.2.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.2.2 Predictive Testing - Volumes, Prices, Revenues
    • 7.2.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.2.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.2.5 All Genetic testing - Volumes, Prices, Revenues
  • 7.3 South Korea
    • 7.3.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.3.2 Predictive Testing - Volumes, Prices, Revenues
    • 7.3.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.3.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.3.5 All Genetic testing - Volumes, Prices, Revenues
  • 7.4 India
    • 7.4.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.4.2 Predictive Testing - Volumes, Prices, Revenues
    • 5.1.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.4.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.4.5 All Genetic testing - Volumes, Prices, Revenues
  • 7.5 Australia
    • 7.5.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.5.2 Predictive Testing - Volumes, Prices, Revenues
    • 7.5.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.5.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.5.5 All Genetic testing - Volumes, Prices, Revenues
  • 7.6 Rest of Asia Pacific
    • 7.6.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 7.6.2 Predictive Testing - Volumes, Prices, Revenues
    • 7.6.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 7.6.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.6.5 All Genetic testing - Volumes, Prices, Revenues

8. Country Markets - Latin America, Africa & The Middle East

  • 8.1 Brazil
    • 8.1.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 8.1.2 Predictive Testing - Volumes, Prices, Revenues
    • 8.1.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 8.1.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 8.1.5 All Genetic testing - Volumes, Prices, Revenues
  • 8.2 Mexico
    • 8.2.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 8.2.2 Predictive Testing - Volumes, Prices, Revenues
    • 8.2.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 8.2.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 8.2.5 All Genetic testing - Volumes, Prices, Revenues
  • 8.3 Rest of Latin America
    • 8.3.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 8.3.2 Predictive Testing - Volumes, Prices, Revenues
    • 8.3.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 8.3.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 8.3.5 All Genetic testing - Volumes, Prices, Revenues
  • 8.4 Africa & The Middle East
    • 8.4.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 8.4.2 Predictive Testing - Volumes, Prices, Revenues
    • 8.4.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 8.4.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 8.4.5 All Genetic testing - Volumes, Prices, Revenues

9. Global Market Summary

  • 9.1 Global Market
    • 9.1.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
    • 9.1.2 Predictive Testing - Volumes, Prices, Revenues
    • 9.1.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
    • 9.1.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 9.1.5 All Genetic testing - Volumes, Prices, Revenues

10. The Future of Genetic Testing

Appendices

  • I. United States Medicare System: January 2016 laboratory Fees Schedule - National Limit and Midpoint
  • II Methodology
  • II.1 Authors
  • II.2 Sources

Table of Tables

  • Table 1 Most Common Traditional Genetic Disorders
  • Table 2 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 3 Market Players by Type
  • Table 4 The Different Types of Genetic Tests
  • Table 5 Five Factors Driving Growth
  • Table 6 Four Factors Limiting Growth
  • Table 7 Key Diagnostic Laboratory Technology Trends
  • Table 8 Next Generation Sequencing Technologies - Speed and Cost
  • Table 9 USA Prenatal and Newborn - Volume Price and Revenue Forecast
  • Table 10 USA Predictive - Volume Price and Revenue Forecast
  • Table 11 USA Pharmacogenomic Testing - Volume Price and Revenue Forecast
  • Table 12 USA Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 13 USA All Genetic testing - Volume Price and Revenue Forecast
  • Table 14 Canada Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 15 Canada Predictive Testing - Volume Price and Revenue Forecast
  • Table 16 Canada Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 17 Canada Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 18 Canada All Genetic testing - Volume Price and Revenue Forecast
  • Table 19 France Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 20 France Predictive Testing - Volume Price and Revenue Forecast
  • Table 21 France Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 22 France Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 23 France All Genetic testing - Volume Price and Revenue Forecast
  • Table 24 Germany Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 25 Germany Predictive Testing - Volume Price and Revenue Forecast
  • Table 26 Germany Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 27 Germany Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 28 Germany All Genetic testing - Volume Price and Revenue Forecast
  • Table 29 U.K. Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 30 U.K. Predictive Testing - Volume Price and Revenue Forecast
  • Table 31 U.K. Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 32 U.K. Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 33 U.K. All Genetic testing - Volume Price and Revenue Forecast
  • Table 34 Spain Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 35 Spain Predictive Testing - Volume Price and Revenue Forecast
  • Table 36 Spain Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 37 Spain Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 38 Spain All Genetic testing - Volume Price and Revenue Forecast
  • Table 39 Italy Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 40 Italy Predictive Testing - Volume Price and Revenue Forecast
  • Table 41 Italy Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 42 Italy Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 43 Italy All Genetic testing - Volume Price and Revenue Forecast
  • Table 44 Russia Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 45 Russia Predictive Testing - Volume Price and Revenue Forecast
  • Table 46 Russia Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 47 Russia Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 48 Russia All Genetic testing - Volume Price and Revenue Forecast
  • Table 49 Rest of Europe Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 50 Rest of Europe Predictive Testing - Volume Price and Revenue Forecast
  • Table 51 Rest of Europe Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 52 Rest of Europe Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 53 Rest of Europe All Genetic testing - Volume Price and Revenue Forecast
  • Table 54 China Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 55 China Predictive Testing - Volume Price and Revenue Forecast
  • Table 56 China Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 57 China Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 58 China All Genetic testing - Volume Price and Revenue Forecast
  • Table 59 Japan Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 60 Japan Predictive Testing - Volume Price and Revenue Forecast
  • Table 61 Japan Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 62 Japan Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 63 Japan All Genetic testing - Volume Price and Revenue Forecast
  • Table 64 South Korea Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 65 South Korea Predictive Testing - Volume Price and Revenue Forecast
  • Table 66 South Korea Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 67 South Korea Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 68 South Korea All Genetic testing - Volume Price and Revenue Forecast
  • Table 69 India Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 70 India Predictive Testing - Volume Price and Revenue Forecast
  • Table 71 India Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 72 India Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 73 India All Genetic testing - Volume Price and Revenue Forecast
  • Table 74 Australia Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 75 Australia Predictive Testing - Volume Price and Revenue Forecast
  • Table 76 Australia Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 77 Australia Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 78 Australia All Genetic testing - Volume Price and Revenue Forecast
  • Table 79 Rest of Asia Pacific Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 80 Rest of Asia Pacific Predictive Testing - Volume Price and Revenue Forecast
  • Table 81 Rest of Asia Pacific Pharmacogenomics Testing - Volume Price and Revenue Forecast.. 193
  • Table 82 Rest of Asia Pacific Direct to Consumer Testing - Volume Price and Revenue Forecast. 194
  • Table 83 Rest of Asia Pacific All Genetic testing - Volume Price and Revenue Forecast
  • Table 84 Brazil Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 85 Brazil Predictive Testing - Volume Price and Revenue Forecast
  • Table 86 Brazil Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 87 Brazil Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 88 Brazil All Genetic testing - Volume Price and Revenue Forecast
  • Table 89 Mexico Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 90 Mexico Predictive Testing - Volume Price and Revenue Forecast
  • Table 91 Mexico Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 92 Mexico Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 93 Mexico All Genetic testing - Volume Price and Revenue Forecast
  • Table 94 Rest of Latin America Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 95 Rest of Latin America Predictive Testing - Volume Price and Revenue Forecast
  • Table 96 Rest of Latin America Pharmacogenomics Testing - Volume Price and Revenue Forecast 200
  • Table 97 Rest of Latin America Direct to Consumer Testing - Volume Price and Revenue Forecast . 201
  • Table 98 Rest of Latin America All Genetic testing - Volume Price and Revenue Forecast
  • Table 99 Africa & Middle East Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 100 Africa & Middle East Predictive Testing - Volume Price and Revenue Forecast
  • Table 101 Africa & Middle East Pharmacogenomics Testing - Volume Price and Revenue Forecast 202
  • Table 102 Africa & Middle East Direct to Consumer Testing - Volume Price and Revenue Forecast 203
  • Table 103 Africa & Middle East All Genetic testing - Volume Price and Revenue Forecast
  • Table 104 Global Prenatal and Newborn Testing - Volume Price and Revenue Forecast
  • Table 105 Global Predictive Testing - Volume Price and Revenue Forecast
  • Table 106 Global Pharmacogenomics Testing - Volume Price and Revenue Forecast
  • Table 107 Global Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 108 Global All Genetic testing - Volume Price and Revenue Forecast
  • Table 109 2016 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 2 Chart of Market Shares of Key Genetic Companies
  • Figure 3 Percentage of World Population Over
Back to Top